drugset / Trial / NCT00716794
A Phase I/II Study of HE3235 in Patients With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.
Timeline
- Start
- 2008-07
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HE3235 | Small molecule | — | Oral |